ArticleBreast cancer (Dove Medical Press)2026
MCV-Neutropenia Risk Score and Overall Survival in HR+/HER2- Advanced Breast Cancer: A Multicenter Retrospective Landmark Analysis.
Article in Breast cancer (Dove Medical Press), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Predicting long-term benefit from CDK4/6 inhibitors in HR+/HER2- advanced breast cancer remains challenging in routine clinical practice. We evaluated whether a simple composite index integrating early neutropenia and mean corpuscular volume change, termed the MCV-Neutropenia Risk Score (MNRS), could improve early prognostic stratification. Methods: In this multicenter retrospective study, 432 patients were screened, and 273 patients who were alive and evaluable at the predefined 3-month landmark were included in the final analysis. Grade 2-3 neutropenia during the first three months and ΔMCV ≥10 fL at the landmark assessment were assigned one point each to construct the MNRS (range, 0-2). Landmark overall survival (OS), measured from the 3-month landmark, was evaluated using Kaplan-Meier estimates and Cox proportional hazards regression. Internal bootstrap validation with 1,000 resamples was performed. Results: After a median landmark follow-up of 44.9 months, 77 deaths were recorded. Grade 2-3 neutropenia occurred in 205 patients (75.1%), ΔMCV ≥10 fL in 93 patients (34.1%), and 66 patients (24.2%) had an MNRS of 2. Higher MNRS categories were associated with progressively more favorable landmark OS (log-rank p = 0.009). In the final center-stratified multivariable model, each one-point increase in MNRS was independently associated with a lower risk of death (HR 0.555, 95% CI 0.381-0.808; p = 0.002). Internal bootstrap validation supported the stability of MNRS in the multivariable model. Conclusion: Among patients who were alive and evaluable at the 3-month landmark, higher MNRS was independently associated with more favorable subsequent landmark OS. MNRS may represent an exploratory and complementary approach to early risk stratification using routinely available hematologic parameters. Because both neutropenia and MCV changes may be influenced by treatment exposure and other clinical factors, prospective external validation is required before clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.